Nu-Med Plus, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 14, 2019 at 02:26 pm EST
Share
Nu-Med Plus, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 146,213 compared to USD 522,069 a year ago. Net loss was USD 150,576 compared to USD 526,848 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago. For the nine months, operating loss was USD 813,726 compared to USD 833,345 a year ago. Net loss was USD 826,955 compared to USD 847,889 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.
NU-MED PLUS, INC. 